PEGylated Polymeric Nanoparticle Conjugates for Osteoarthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nano-delivery systems for treating osteoarthritis and other conditions face challenges such as short drug half-life, low efficacy, and high costs due to inefficient drug delivery and lack of long-term therapeutic effects, with existing treatments providing only palliative relief and not addressing the underlying pathogenesis of osteoarthritis.
Innovation Solution
Development of polymeric nanoparticle conjugates with a core polymeric matrix linked to adenosine or its agonists via hydrophilic polymer moieties, which provide sustained release and increased receptor activation, thereby promoting wound healing, reducing inflammation, and preserving articular cartilage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional nano-delivery systems are used, then drug delivery is achieved, but the drug half-life is short and clearance by the reticuloendothelial system occurs rapidly
Solution Approach 1:
The patent modifies the surface properties of nanoparticles by conjugating polyethylene glycol (PEG) chains to the nanoparticle surface, changing the physical-chemical parameters of the nanoparticle surface. This PEGylation creates a hydrophilic corona that reduces protein adsorption and reticuloendothelial system recognition, thereby extending drug half-life and reducing clearance rates.
Solution Approach 2:
The patent creates composite nanoparticle structures combining a core material (for drug loading) with a PEGylated shell layer. This composite structure integrates the drug delivery functionality of the core with the stealth properties of the PEG shell, achieving both sustained release and reduced clearance by the reticuloendothelial system.
2Reliability
If current treatments for osteoarthritis are used, then symptomatic relief is provided, but long-term therapeutic effects and disease modification are not achieved
Solution Approach 1:
The patent employs nanoparticles pre-loaded with therapeutic agents (such as adenosine or its agonists) that are designed to provide sustained release over extended periods. This preliminary preparation ensures that the therapeutic agent is delivered continuously to the target site, achieving both immediate symptomatic relief and long-term disease-modifying effects.
Solution Approach 2:
The patent designs nanoparticle systems with controlled release mechanisms that maintain continuous therapeutic agent delivery to the osteoarthritic joint. This continuous action ensures sustained symptomatic relief while simultaneously providing long-term protective effects on cartilage, addressing both immediate and chronic aspects of the disease.
3Quantity of substance
If high doses of nanoparticles are administered to overcome clearance issues, then drug concentration is increased, but toxicity increases
Solution Approach 1:
The patent uses PEG chains as intermediary layers on the nanoparticle surface that act as a protective barrier. This intermediary PEG shell reduces direct interaction between the nanoparticle core and biological systems, thereby extending circulation time and allowing lower doses to achieve therapeutic concentrations, thus reducing toxicity while maintaining effective drug levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymeric nanoparticle conjugates offer a more effective and sustained delivery of adenosine or its agonists, leading to improved wound healing, reduced inflammation, and preservation of articular cartilage, providing a potential long-term therapeutic solution for osteoarthritis and other conditions.
Implementation Method 1
L is a surface linker group, wherein the surface linker group is a hydrophilic polymer moiety
Data Source
AI summary
The present invention relates to a polymeric nanoparticle conjugate of formula (I). The present invention also relates to pharmaceutical compositions including these polymeric nanoparticle conjugates, and methods of preparation and use thereof.